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Abstract
Background: Radionuclide therapy can be individualized by performing dosimetry.
To determine absorbed organ doses in 177Lu-DOTATATE therapy, three methods
based on activity concentrations are currently in use: the small volume of interest
(sVOI) method, and two methods based on large VOIs either on anatomical CT (aVOI)
or on thresholds on functional images (tVOI). The main aim of the present work was
to validate the sVOI in comparison to the other two methods regarding agreement
and time efficiency. Secondary aims were to investigate inter-observer variability for
the sVOI and the change of functional organ volumes following therapy.
Methods: Thirty patients diagnosed with neuroendocrine tumours undergoing
therapy with 177Lu-DOTATATE were included. Each patient underwent three SPECT/
CT scans at 1, 4 and 7 days after the treatment. Three independent observers
calculated absorbed doses to the right and left kidney and the spleen using sVOI
and one observer used aVOI. For tVOI, the absorbed doses were calculated based on
automatically drawn isocontours around the organs at different thresholds (42, 50, 60
and 70 %). The inter-observer difference between the calculated absorbed doses
for sVOI was calculated, and the differences between the three methods were
computed. Ratios of organ volumes acquired at days 1, 4 and 7 versus the volume
at day 1 were calculated for the tVOI method.
Results: The differences in results of the absorbed dose calculations using all the sVOI
and tVOI were small (<5 %). Absorbed dose calculations using aVOI differed slightly
more from these results but were still below 10 %. The differences between the three
dose calculation methods varied between <5 and 10 %. The organ volumes derived
from the tVOI were independent of time for the spleen while they decreased with time
for the kidneys. The fastest analysis was performed with the sVOI method.
Conclusions: All three dose calculation methods rendered comparable results with
small inter-observer differences for sVOI. Unlike the spleen, the functional volume of the
kidneys decreased over time during therapy, which suggests that the absorbed dose
calculation for the kidneys on activity concentrations should be performed for each time
point. The sVOI is the preferred method for calculating absorbed doses in solid organs.
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Background
During the last decades, cancer survival in general has improved [1]. Several reports sug-
gesting improved outcome in patients responding to PRRT have been published [2–4].
This is true for all treatment modalities including surgery, chemotherapy and radiation
therapy. It has been shown that patients with somatostatin receptor positive neuroendo-
crine tumours can be treated with good results using peptide receptor radionuclide therapy
(PRRT) with 177Lu-DOTA-D-Phe1-Tyr3-octreotate (177Lu-DOTATATE) [3–7]. The thera-
peutic effect is correlated to the delivered absorbed dose to the tumours for external beam
radiation therapy (EBRT) and the same effect has been shown also for systemic treatment
with ionizing radiation resulting from PRRT using 90Y-[DOTA]-D-Phe1-Tyr3-octreotide
(90Y-DOTATOC) [8], and more recently in the case of pancreatic NETs using
177Lu-DOTATATE [9]. To maximize the tumour effect, the absorbed dose in the
tumours should be as high as possible, while at the same time the absorbed doses
to normal organs should be kept within the safety margins. The possibility of in-
creased administered activity in therapy with 177Lu-DOTATATE is often limited by
concern about toxicity resulting from radiation damage to healthy organs (mainly
the bone marrow and kidneys) [4, 10–14]. An earlier study with 2 Gy as upper
limit to the bone marrow and 23 Gy to the kidneys indicated that in most cases,
the kidneys are the dose-limiting organs [15]. In two recent studies the first by
Sabet et al. [16] on nephrotoxicity after PRRT with 177Lu-DOTATATE with accu-
mulated administered activities from 14.8 to 37.8 GBq, only one of the 74 patients
showed significant renal toxicity (≥grade 3). In the second study by Bodei et al.
[17] in 290 patients receiving PRRT with 177Lu-DOTATATE with accumulated ad-
ministered activities from 1.1 to 49.2 GBq, none of the patients showed significant
(≥grade 3) nephrotoxicity while nine showed significant (≥grade 3) haematological
toxicity. This indicates a potential to increase the administered activity further for
individual patients.
Twenty-three Gy is the limit generally accepted for the absorbed dose to the kidney in ex-
ternal beam radiotherapy, based on the observation that TD5/5 (the absorbed dose where
5 % of the patients developed radiation nephritis) for the whole kidney is 23 Gy [18]. Due to
inhomogeneous distribution at a microscopic level in PRRT with 177Lu-DOTATATE, higher
absorbed doses can probably be accepted, and Konijnenberg et al. [19] argued for a limit
of 29 Gy to the kidneys. In view of the low-dose rate and the ongoing continuous radi-
ation in PRRT, the absorbed dose limits may be even higher. A biological effective dose
(BED) up to 45 Gy has been suggested [20]; however, the influence of clinical risk factors
on kidney tolerance has been reported [12, 14] and might be taken into account in the
future.
In order to estimate the absorbed dose in the risk organs in PRRT with 177Lu-
DOTATATE, the activity distribution and kinetics over time are needed. Since it is gener-
ally difficult to free-project the kidneys from surrounding organs and tumours in NET
patients receiving therapy with 177Lu-DOTATATE, dosimetry using whole body imaging
(2D) is insufficient [21]. Therefore, robust methods to calculate organ doses based on 3-D
imaging need to be applied.
As previously demonstrated in a simulation study [22] and clinically [23], the
absorbed dose for the kidneys originates mainly from the organs themselves (self-dose)
because almost 90 % of 177Lu decay is by emission of short-range beta particles. Only a
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few percent of the absorbed dose result from the cross-dose from gamma radiation
from the surrounding organs. The self-dose therefore yields a very good estimate of the
absorbed dose and can be calculated by multiplying the activity concentration for an
organ at the given time point by an almost size-independent activity concentration dose
factor (ACDF), as published earlier [15, 21]. Since absorbed dose is absorbed energy
per mass and the energy deposition from 177Lu generally can be assumed to be
absorbed locally, it is of uttermost importance to know the concentration of decays,
not only the total number of decays in an organ, at each time point. It has been
demonstrated earlier [20, 21] that the estimated volumes of the kidneys in the patients
receiving therapy with 177Lu-DOTATATE can have a large intra-patient variability
depending on the method used to determine the volume.
Different methods can be used to measure organ activity concentrations from single
photon emission tomography (SPECT) with low-dose computed tomography (CT) for
attenuation correction (SPECT/CT). The most frequently used method is to delineate
the whole organ either in the anatomical (CT) or the functional (SPECT) image. A
second method, introduced in earlier reports [15, 21], is to measure the concentration
using a small VOI with a specified volume yielding the activity concentration in a
defined small volume within the organ. Comparison between dosimetry based on
manually delineated whole organ VOIs versus small VOIs on SPECT images has shown
acceptable agreement [21].
In times where financial resources are limited and time is a valuable resource, it is of
importance that the calculation of the absorbed dose can be performed as fast as
possible. For this reason, the setup time to calibrate the equipment has to be taken into
account as well as the time spent for the dose calculation.
The main aim of this work was to compare dosimetry based on the small VOI (sVOI)
method versus threshold VOI on functional images (tVOI) method and VOIs on anatom-
ical CT images (aVOI) method. Secondary aims were to investigate the inter-observer vari-
ability in the sVOI method, the impact of the threshold applied in the tVOI method, the
changes in functional volume (the volume where the 177Lu is located in the organ) over
time from treatment, to study the differences in kidney volume estimated by tVOI and
aVOI in patients receiving 177Lu-DOTATATE therapy, and to determine the time needed
to perform the absorbed dose calculation using the different methods. All methods were
applied to both kidneys and spleen in order to examine whether any differences between
methods were related to the complex structure of the kidneys or method dependent.
Methods
Patients
Thirty patients (17 female and 13 male) with metastatic somatostatin receptor-
expressing neuroendocrine tumours treated with 177Lu-DOTATATE were included in
this study and all patients met previously described inclusion criteria [21]. Due to
adjacent tumour uptake that made the tVOI method impossible to use, one left kidney
and three right kidneys were excluded for all methods. For the anatomical CT images
method, one more patient was excluded due to missing CT data.
177LuCl3 was purchased from IDB, and DOTATATE was a generous gift from Erasmus
Medical Centre, Rotterdam.
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Compliance with ethical standards
There is no external funding, and all authors declare no conflict of interest.
Since September 2010, all patients have been included after giving their written
informed consent into a prospective study (EudraCT no. 2009-012260-14) approved by
the Regional Ethical Review Board in Uppsala. Before that time, patients were admitted
after giving their informed consent on a single-patient basis for compassionate use with
individual permission of the Swedish Medical Products Agency.
Image acquisition
On all 30 patients, SPECT/CT of the abdomen was performed 1, 4 and 7 days after
administration of the first therapeutic cycle of 7.4 GBq 177Lu-DOTATATE. Imaging was
performed on an Infinia (International General Electric, General Electric Medical Systems,
Haifa, Israel) dual-headed gamma camera equipped with 3/8” NaI(Tl)-crystals with VPC-5
(MEGP) collimators. A 20 % energy window was placed around the dominant 208.4 keV
gamma ray energy of 177Lu to make the measurements. SPECT/CT of the upper abdomen
including organs at risk (kidneys, liver and spleen), applying 120 frames with a 30-s ex-
posure time per frame (total acquisition time for SPECT is then 30 min), was performed.
For reconstruction, the Ordered Subsets Expectation Maximisation (OSEM) algorithm
included in the Xeleris 3.0 workstation (International General Electric, General Electric
Medical Systems, Haifa, Israel) was used with earlier default settings (iterative reconstruc-
tion with eight subsets and four iterations followed by a Hann filtering with a cut-off of
0.85). The images were attenuation corrected with the concomitantly CT-created
attenuation map acquired on a four-channel CT scanner (Hawkeye, 140 kVp, 3.0 mA and
half rotation).
Image analysis
All images were analysed by the 3 methods sVOI, aVOI and tVOI.
sVOI method
Analysis was performed by three observers using small spherical volumes of interests
(VOIs; 4 ml) in both kidneys and spleen, using in-house developed software within the
Hermes platform on a Hermes HNAC workstation with Gold 2.9 (HERMES, Stockholm,
Sweden). Observers were instructed to place VOIs over the region of highest activity in
the healthy organ, as described previously [21].
tVOI method
Threshold measurements were performed for both kidneys and spleen using 42, 50, 60
and 70 percent of the maximum in the organ as limit. The 42 % threshold has previously
showed to most closely resemble the true volume [24], and the higher thresholds were
chosen to see what impact a higher threshold would have on the quantification. The
threshold measurements were performed using the VOI tool in NEDPAS Software Tools
[25] Version Built 26042009 written by R. Boellaard, VU University Medical Center,
Amsterdam, The Netherlands.
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aVOI method
The organs were delineated on the CT images using Dosimetry toolkit software
included in the Xeleris 3.0 workstation (International General Electric, General Electric
Medical Systems, Haifa, Israel). We attempted to use a threshold on the Hounsfield
scale for the delineation on the CT images. However, the delineation according to the
Hounsfield scale did not yield acceptable anatomic delineation, so the final organ
definition was completely manual.
Calibration of SPECT images was based on a 100-ml sphere containing a known
activity concentration. The sphere was placed inside a thorax phantom, which was
scanned repeatedly (18). The sensitivity of the camera is independent of measurement
technique, still the sensitivity factor to be used will be different for all techniques and
cut-off levels since the proportion of the peripheral parts of the volume (where edge
effects take place) that are included is method/cut-off dependent.
Phantom measurements filled with a high activity concentration imaged weekly
for 10 weeks confirmed that there were no dead time issues in the patient
measurements.
Activity concentrations were determined for all of these observers/methods for
each time point, and time-integrated activity concentration was calculated as the
area under the curve of a single exponential fit (from injection start to infinity) to
the time–activity concentration curve. In the 42, 50, 60 and 70 % threshold VOIs,
the measured functional volumes were determined separately for each time point
while for the anatomical (CT) images the volumes were defined on the 24-h
images and transferred to the 3-day and 7-day images, so only one volume was
determined and used for purposes of calculating organ activity concentration.
Changes between functional volumes obtained at different thresholds and different
time points were calculated as ratios relative to the 1-day image.
Absorbed dose calculations
Absorbed doses to both kidneys and spleen were calculated by multiplication of time-
integrated organ activity concentration with the appropriate ACDF, thus considering
only the self-dose.
Time to perform an absorbed dose calculation
The time required to calculate the absorbed dose for each of the three methods was
measured from start of calculation until the report was completed.
Statistical methods
A Wilcoxon matched-pair signed rank test was used to test for a statistically significant
difference between the organ volumes at different time points estimated by the tVOI
method. P values less than 0.05 were treated as statistically significant and less than
0.0001 as highly statistically significant.
Absorbed dose data were analysed in two ways: 1) the percent difference between
one observer/method versus another and 2) as a correlation coefficient between one
observer/method versus another.
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Results
Kidney and spleen volumes evaluated by tVOI and aVOI methods are presented as a
box-whiskers plot in Fig. 1. The kidney volumes evaluated by using the threshold
method with 42 % cut-off had a median (min–max) value of 170 (107–283) ml for the
right kidney (26 patients) and 195 (136–276) ml for the left kidney (29 patients). With
a threshold of 50 %, the calculated volume was 140 (87–239)ml for the right kidney and
160 (106–229)ml for the left kidney. The CT delineated volume was 169 (90–342)ml for
the right kidney (26 patients) and 193 (111–315)ml for the left kidney (28 patients). There
was no good correlation in the volumes of the left and right kidneys on an intra-patient
basis. When significant differences in size and/or absorbed dose occurred, the maximum
absorbed dose was used for limitation of the therapy.
Figure 2 presents a box-whiskers plot of the changes in the functional volume and
Table 1 shows the percent difference in the functional volume of kidneys and spleen
Fig. 1 Organ volumes (ml) 1 day after treatment in the right kidney (red), left kidney (blue) and spleen
(green) determined with functional images using 42, 50, 60 and 70 % cut-off and anatomical CT
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over time using the threshold method with the different cut-offs (42, 50, 60 and 70 %).
For the spleen, no obvious difference was seen between the 1-, 4- and 7-day measure-
ments besides a small increase from day 1 to day 4 that resolved at day 7. For the
kidneys, a consistent decrease of the functional volume over time was observed,
independent of the cut-off level. There was a large patient variability and a clear
difference depending on the applied cut-off. P values showing significant and highly
significant differences are indicated in Table 1.
The differences in organ volume presented above result in differences in organ activity
concentrations and consequently have implications for absorbed dose estimates.
In Fig. 3, an example of the difference in the absorbed dose calculations between two
cut-offs (42 versus 60 %) using the tVOI method is presented as a Bland-Altman plot.
Fig. 2 Ratio of volumes 1, 4 and 7 days versus the day-1 volume in the right kidney (red), left kidney (blue)
and spleen (green) using 42, 50, 60 and 70 % cut-off
Table 1 Percentage difference between volumes for different cut-offs using the tVOI method. Data
are presented as median (min; max)
Days 42 % 50 % 60 % 70 %
Right kidney 1 vs 4 −6.6 (−34.1; 6.1)* −7.8 (−42.8; 4.3)** −12.3 (−55.6; 12.2)** −20.7 (−70.8; 32.9)**
1 vs 7 −23.3 (−60.5; 5.0)** −27.8 (−71.8; 3.3)** −35.2 (−83.5; −1.5)** −44.7 (−93.6; 5.9)**
4 vs 7 −15.5 (−40.1; 15.3)** −17.3 (−51.1; 16.3)** −24.7 (−63.7; 13.0)** −29.3 (−80.9; 38.3)**
Left kidney 1 vs 4 −5.9 (−35.8; 26.8)** −6.0 (−37.0; 23.8)** −8.9 (−46.3; 24.0)** −15.9 (−68.2; 33.2)*
1 vs 7 −14.7 (−59.0; 7.1)** −17.0 (−69.4; 7.6)** −25.3 (−79.9; 13.7)** −39.5 (−88.4; 17.3)**
4 vs 7 −9.0 (−44.5; 26.5)** −11.8 (−55.1; 19.0)** −17.0 (−65.9; 20.6)** −27.4 (−76.3; 37.0)**
Spleen 1 vs 4 5.5 (−25.5; 50.9)* 8.1 (−27.6; 55.5)* 7.5 (−30.5; 46.0)* 1.3 (−33.6; 70.1)
1 vs 7 −2.1 (−33.8; 52.0) −2.4 (−36.4; 53.3) −6.1 (−41.9; 46.2) −12.4 (−56.8; 46.2)*
4 vs 7 −6.6 (−33.7; 24.6)* −9.6 (−36.7; 21.8)** −13.4 (−48.7; 27.9)** −16.0 (−57.3; 48.7)**
Two-tailed P values from the Wilcoxon matched-pair signed rank tests between the functional volume measurements
was also calculated to evaluate if the differences were significant
*P values lower than 0.05 were significant; **P value lower than 0.001 was highly significant
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Percentage differences in the absorbed dose calculations for all cut-off values used in
the tVOI method are presented in Table 3. Figure 3 shows the tendency to slightly
lower absorbed dose when using 42 % rather than 60 % threshold, confirmed in Table 3.
However, all correlation coefficients were 0.99 and above. Despite the small differences,
there was a good agreement between the different cut-off levels (less than 5 %).
Percentage differences in the absorbed dose calculations for all three observers using
the sVOI method are presented in Table 2 and for observer 1 versus observer 2 as a
Bland-Altman plot in Fig. 4. The dashed lines in the Bland-Altman plots correspond to
1.96 SD corresponding to double-sided P = 0.05. All correlation coefficients were 0.96
and above. Inter-observer variability in percentage difference is generally low (less than 5 %)
showing a good agreement between the different observers using the sVOI method for
absorbed dose calculations.
Bland-Altman plots showing differences between all three methods (sVOI, tVOI and
aVOI) for the right kidney are presented in Fig. 5. The percentage differences for all the
organs are presented in Table 4. All correlation coefficients were 0.91 and above
showing a good correlation. There is good agreement between the sVOI and tVOI
methods (differences less than 10 %). In general, the aVOI method generated 5 to
10 % lower absorbed doses with differences up to 25 %.
The time to perform absorbed dose calculation measurements using different
methods depended heavily on both patient and observer. The results can only be taken
as an indication of the time needed to complete the calculation. The time required for
Fig. 3 Percentage difference against mean for two cut-off values using tVOI method calculating absorbed
dose to the right kidney
Table 2 Percentage difference between absorbed dose calculations for different observers using
the sVOI method. Data are presented as median (min; max)
Observer 2 Observer 3
Right kidney Observer 1 0.8 (−4.8; 5.0) 3.6 (−4.5; 16.8)
Observer 2 2.9 (−5.8; 18.7)
Left kidney Observer 1 1.2 (−4.4; 9.6) 1.8 (−6.6; 12.7)
Observer 2 0.7 (−8.9; 15.5)
Spleen Observer 1 −0.6 (−7.4; 11.1) 0.0 (−16.0; 11.9)
Observer 2 0.7 (−16.9; 9.6)
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both the sVOI and the aVOI to calculate the absorbed dose, including the left and right
kidneys and spleen, ranged between 15 and 45 min, while for the tVOI this ranged
between 3 and 5 h for the three organs independent of number of thresholds.
Discussion
To our knowledge, the present work is the first study comparing inter-operator variability
and method dependence for radiation dosimetry of 177Lu-DOTATATE in a group of
patients in a systematic way including method-specific sensitivity (accounting for edge
effects) in the calculations. We also believe this to be the first study investigating the
changes in functional organ volume over time from administration of PRRT, with
implications for dosimetry calculation. This study is not aiming at an analysis of
absorbed doses to functional sub-units but calculation of average absorbed dose to
the kidneys.
A range of publications during recent years has reported on the clinical value of
radionuclide therapy directed towards somatostatin receptors for therapy of patients
with neuroendocrine tumours [3, 4, 6, 13]. Still, many issues remain to be solved in order
to improve and personalize the therapy [26]. In the literature, a general agreement on the
importance of individualized therapy is noted, where dosimetry is one tool to achieve an in-
dividual risk-assessment for sensitive organs [27]. Kidney toxicity is a limiting factor for
radionuclide therapy with somatostatin analogs, especially when using 90Y [4, 14, 20]. The
Fig. 4 Percentage difference against mean for two observers calculating absorbed dose to the right kidney
using sVOI method
Fig. 5 Percentage difference against mean in calculation of absorbed dose to the right kidney using
different measuring techniques a sVOI vs. tVOI, b sVOI vs. aVOI and c tVOI vs. aVOI
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observed kidney toxicity for therapy with 177Lu-DOTATATE is lower, with a maximum
tolerable absorbed dose yet to be defined [3, 27].
The work of our own group has been dedicated to developing a robust and clinically
applicable dosimetry protocol for solid organs based on 3-D imaging [15, 21]. In
accordance with several other groups, we found 177Lu-DOTATATE PRRT dosimetry
based only on 2-D scanning problematic due to inherent difficulties of delineating healthy
organ uptake from tumours and physiological uptake as in the bowel [12, 28, 29].
Organ dosimetry in radionuclide therapy is highly dependent on the correct input
data defined by activity concentrations measured over time. The volume calculation for
kidneys has been problematic, and the results are highly dependent on the method
applied [30]. The weight of normal kidneys varies with body surface and gender and is
in the range of 130 to 160 g for men and 120 to 150 g for women [31]. The volume
estimations from the aVOI and tVOI with 42 % and 50 % cut-off agree well with earlier
published data on kidney volumes (range 100 to 300 ml) in patients with neuroendo-
crine tumours receiving PRRT [20, 21], and also with those achieved in healthy adults
by using an MRI-based method, that showed high agreement with ex vivo data [30].
The estimated volumes by tVOI using 60 and 70 % cut-offs were too small to reflect
the true volumes. By using dedicated contrast enhanced CT, the outlining of the
kidneys should theoretically be more anatomically correct. However, in this study, the
kidney volumes were calculated from low-dose CT performed for attenuation correc-
tion. Because the software used for the organ delineation is dependent on a distinct
attenuation contrast between the kidney and surrounding adipose tissue that some-
times was hard to define, the resulting estimated CT volumes may therefore be less
precise. Another limitation in this study was that the aVOI method was only performed
once by one observer. The large volume differences between methods highlight the im-
portance to find a method that can render activity concentrations without the necessity
of defining the whole organ volume.
The changes over time in functional volume observed in the threshold measurements
for the spleen were minor and not significant when comparing between day 1 and 7.
For the kidneys, the ratios between late and early measurements after therapy showed a
clear decrease for all cut-off levels. Our data suggest that the functional volume of the
kidneys decreases over time during 177Lu-DOTATATE therapy, which is of clinical
interest. In reports by other authors [28, 32, 33], the kidney volume has been defined at
one time point and used as a correction for 2-D-based dosimetry calculations, assum-
ing that the (functional) volume of the kidneys is constant during the whole radio-
nuclide therapy. In the light of our reported findings, this assumption might for the
majority of the patients lead to an underestimation of the absorbed dose to the kidneys.
The sequential decrease in functional volume influences the calculation of the absorbed
dose considerably and might result in an absorbed dose difference of about 10 % and
sometimes even more. In patient dosimetry, this fact introduces another factor of un-
certainty in the dose calculation of the kidneys, besides the above-mentioned inherent
problems when only 2-D data are used.
The reason for the observed volume change during therapy can only be specu-
lated about. Increased blood flow to the kidneys as an immediate reaction to the
therapy might be one contributing explanation, as can be the co-infusion of amino
acids during therapy.
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It is of note, though, that the different cut-offs (42, 50, 60 and 70 %) applied with
tVOI resulted in almost the same absorbed dose. This indicates, that a precise estimate
of the actual kidney volume is not necessary as long as the applied cut-off value is in
the range of 42 to 70 %, the activity concentration is calculated for every time point
and that the same cut-off is used for calibration.
Table 2 shows that the percentage difference between the absorbed dose calculations
of the three different observers using the sVOI method is small, indicating a robust
method. The differences are for most patients between 2 and 5 %, rarely above 5 % and
only occasionally up to 10 % in patients with organs close to adjacent tumours that
make the placing of the small volumes problematic/uncertain. Our results show that
the use of sVOI method in this setting renders an operator-independent result. Gener-
ally, there were small, 5 to 10 %, differences in the absorbed dose calculations by using
the tVOI method and the various cut-offs (Table 3). In this study, large VOIs give
slightly higher absorbed doses than the small VOI method. This might seem strange
since small VOI placement was directed to include the highest possible value within
the organ without including tumour tissue. One possible explanation might be that
parts of the small 4 cm3 VOI was influenced by partial volume effect (PVE) in patients
with thinner parenchyma rims, which was not a problem in the calibration setting. We
found a good agreement between the calculated absorbed doses using the sVOI and the
tVOI while the aVOI method rendered 5 to 10 % lower absorbed doses (Table 4 and
Fig. 5). This agrees well with the observation of decreasing functional volume according
to the tVOI method. The correlation coefficients range from 0.92 to 1.00 showing a
Table 3 Percentage difference in the absorbed dose calculations for different cut-offs using the
tVOI method. Data are presented as median (min; max)
50 % 60 % 70 %
Right kidney 42 % 0.9 (−0.6; 2.7) −0.8 (−3.4; 1.9) −2.8 (−5.8; 2.2)
50 % −1.7 (−2.9; −0.5) −3.7 (−6.5; −0.5)
60 % −2.1 (−3.9; 0.3)
Left kidney 42 % 1.0 (−0.1; 2.0) −0.4 (−2.4; 2.0) −2.2 (−6.5; 1.5)
50 % −1.4 (−2.7; 0.0) −3.2 (−6.8; −0.5)
60 % −1.9 (−4.2; −0.5)
Spleen 42 % −1.0 (−0.7; 2.4) −0.2 (−3.1; 3.0) −1.4 (−5.4; 2.0)
50 % −1.2 (−3.1; 0.5) −2.4 (−4.8; 0.0)
60 % −1.3 (−2.7; −0.1)
Table 4 Percentage difference between absorbed dose calculations methods (sVOI, tVOI and
aVOI). sVOI represents sVOI method by observer 1, tVOI represents the 42 % level of the tVOI
method and aVOI represents the CT-based volumes in the aVOI method. Data are presented as
median (min; max)
tVOI aVOI
Right kidney sVOI −3.2 (−17.6; 6.3) 4.5 (−5.0; 25.0)
tVOI 8.4 (−3.8; 22.9)
Left kidney sVOI −3.4 (−10.5; 5.5) 3.9 (−9.8; 24.8)
tVOI 8.0 (−5.8; 29.5)
Spleen sVOI −3.2 (−21.3; 5.5) −2.2 (−19.6; 21.9)
tVOI 1.1 (−17.1; 19.9)
Sandström et al. EJNMMI Physics  (2015) 2:24 Page 11 of 13
strong correlation between the sVOI and the tVOI methods. The correlation
coefficients between the above and data derived from aVOI method were slightly lower
ranging from 0.86 to 0.98, but still showing a good correlation.
Dosimetry based on tVOI and sVOI takes into account possible volume changes
during therapy and therefore seems preferable. The tVOI was by far the most time
consuming (3–5 h per patient) while the other methods were much faster (15–45 min).
For this reason, the sVOI method, in our hands, is the preferred method to calculate
absorbed doses in solid organs.
Conclusions
Volume-based absorbed dose calculations using sVOI method agree well with the tVOI
method while the aVOI method results in slightly lower absorbed doses. In this study,
the inter-observer variability using the sVOI was small and the functional kidney
volume decreased between day 1 and 7 after therapy infusion with 177Lu-DOTATATE.
We conclude that sVOI is the preferred method for calculating absorbed doses, since it
both provides a robust tool for measuring volume concentrations over time in solid
organs and is time efficient.
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